Director Cam Gallagher Buys $323K in Opus Genetics Stock, Signaling Confidence
IRD has more than doubled off its 52-week low of $0.65.
Summary
Opus Genetics Director Cam Gallagher made a substantial open market purchase of $323,693 in company stock, signaling strong insider confidence.
Key Events · Ownership and Investor Activity · IRD
-
Director's Open Market Purchase
Director Cam Gallagher acquired 164,000 shares of Opus Genetics common stock through open market purchases totaling $323,693. The shares were bought at an average price between $1.97 and $1.98 on December 29, 2025.
-
Restricted Stock Unit Grant
Gallagher also received a grant of 33,000 restricted stock units (RSUs) on December 31, 2025, which are scheduled to vest on December 29, 2026, subject to continued service.
Analysis · IRD · Life Sciences
Director Cam Gallagher's significant open market purchase of Opus Genetics stock, totaling over $323,000, indicates strong insider confidence in the company's prospects. This direct investment, alongside a restricted stock unit grant, suggests a positive outlook from a key board member. Investors may view this as a bullish signal, especially for a micro-cap company where insider buying can be particularly impactful.
How filings like this one have moved
In the 30 days to Oct 16, 2026, 29.2% of the 1503 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.39%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IRD was trading at $2.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $138.6M. The 52-week trading range was $0.65 to $2.59. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.